Daniel Swisher compensation by year
Jazz Pharmaceuticals Summary Compensation Table · all 3 fiscal years held| Component | FY2018 | FY2019 | FY2023 |
|---|---|---|---|
| Salary | $608,173 | $667,308 | $834,869 |
| Bonus | $125,000 | $0 | $0 |
| Stock awards | $2,532,058 | $1,960,419 | $4,093,987 |
| Option awards | $2,075,162 | $1,506,379 | $0 |
| Non-equity incentive | $400,000 | $560,000 | $570,000 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $12,948 | $13,302 | $30,118 |
| Total | $5,753,341 | $4,707,407 | $5,528,973 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Jazz Pharmaceuticals plc DEF 14A filed June 14, 2024, accession 0001232524-24-000049, and prior-year filings.
How this page was built: the Jazz Pharmaceuticals plc filed document, accession 0001232524-24-000049. Every figure is read from that document and cited to the page and table it appears in. Filed June 14, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 13,507 | $1,661,361 | — |
| RSU | 13,456 | $1,655,088 | — |
| PSU | 13,456 | $1,655,088 | — |
| RSU | 10,130 | $1,245,990 | — |
| RSU | 7,949 | $977,727 | — |
| RSU | 5,556 | $683,388 | — |
| RSU | 3,333 | $409,959 | — |
| Option | 1,385 | — | $113.10 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Jazz Pharmaceuticals plc's FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Jazz Pharmaceuticals’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Bruce Cozadd | Chairman and Chief Executive Officer | $15,341,235 |
| Daniel Swisher · this page | Former President and COO | $5,528,973 |
| Renée Galá | President and COO | $5,434,388 |
| Robert Iannone | Executive Vice President, Research and Development and Chief Medical Officer | $4,979,077 |
| Kim Sablich | Former Executive Vice President and General Manager, US | $4,165,304 |
| Neena Patil | Executive Vice President and Chief Legal Officer | $3,877,435 |
| Patricia Carr | Senior Vice President and Chief Accounting Officer (Former Interim Principal Financial Officer) | $1,401,028 |
The full Jazz Pharmaceuticals compensation record
free company briefThis page is one person within Jazz Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Jazz Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Jazz Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.